Pain-free precision
Because every detail matters

About GratXray

GratXray is an innovative medical technology company dedicated to transforming diagnostic imaging. As a spin-off from the Paul Scherrer Institute (PSI) and ETH Zurich, we combine world-class research with practical innovation to address real clinical needs.

Our first product, senoa, seeks to revolutionize breast cancer diagnosis with pain-free, high-precision 3D imaging. By eliminating the compression required in traditional mammography and prioritizing patient comfort, we’re making life-saving breast cancer imaging more accessible, especially for women who have avoided it due to discomfort or fear.

Beyond senoa, we are committed to continuous innovation across medical imaging. We leverage cutting-edge technologies developed with our research partners to enhance our devices and explore new clinical applications. Our vision is to set new standards in diagnostic imaging, one breakthrough at a time.

Our Team

Franziska Stemmler

Franziska Stemmler

Hendrik Tevaearai

Hendrik Tevaearai

Lucia Romano

Lucia Romano

Marco Stampanoni

Marco Stampanoni

Co-Founder, Director

Martin Jermann

Martin Jermann

Co-Founder

Martin Stauber

Martin Stauber

Co-founder, CEO

‭+41 44 545 85 30‬

martin.stauber@gratxray.com

Simon Spindler

Simon Spindler

Manager R&D HW Development

Simone Schrading

Simone Schrading

Stefano van Gogh

Stefano van Gogh

Manager QA & RA SW Development

Zhentian Wang

Zhentian Wang

Co-Founder

History

GratXray was founded in 2017 as a spin-off of ETH Zurich and the Paul Scherrer Institut (PSI), bringing over a decade of research expertise in grating-based X-ray interferometry and CT imaging into commercial development. The company was founded by Prof. Dr. Marco Stampanoni, Prof. Dr. Zhentian Wang, Dr. Martin Stauber, and Martin Jermann, together with the Paul Scherrer Institute (PSI).

In its founding year, GratXray received the prestigious Swiss Technology Award 2017 in the Inventors category, marking early recognition of the breakthrough potential of compression-free breast CT imaging. Building on this success, GratXray collaborated with its academic partners to develop a prototype breast CT system integrating a grating-based interferometer, proving the physical principles and solving key engineering challenges. The interdisciplinary team published their development and results in several international scientific journals.

After demonstrating these scientific breakthroughs, GratXray made a strategic decision: to advance clinical breast CT imaging by first addressing challenges accessible with conventional technology, while maintaining a clear path toward grating interferometry integration. This pragmatic approach led to senoa, our dedicated breast CT scanner optimized for immediate clinical deployment, with architecture designed to incorporate grating technology once all development milestones are achieved.

In 2024, GratXray successfully closed its first financing round, enabling expansion of the operational team with key expertise in engineering, regulatory affairs, and quality management. The company established operations at Healthtechpark Zurich in Schlieren, where the team is now focused on bringing senoa to market.

Combining scientific excellence with patient-centered innovation, our multidisciplinary team brings deep expertise in medical physics, imaging technology, intellectual property, and regulatory affairs. As an ISO 13485 certified organization with comprehensive IP protection, we maintain rigorous quality standards as we build a portfolio of breakthrough imaging solutions that improve diagnostic accuracy, patient comfort, and healthcare outcomes.

History

Vision/Mission

Vision
Compassionate and precise medical imaging for all.
 
Mission
Delivering breakthrough imaging technologies that combine clinical precision with exceptional patient comfort.

2017: Founding of GratXray as a PSI and ETH spin-off

2017: Winner of the Swiss Technology Award

2018: Seed funding

2018: Among TOP 100 Swiss Startup Companies

2019: Grant at PSI to develop prototype

2020: First CT-setup on optical table

2024: Investment round

2025: ISO 13485 certification

2025: Filing of patents, design and trademark

Partners and Awards

Partner Logo
Partner Logo
Partner Logo
Partner Logo
Partner Logo
Partner Logo
Partner Logo
Partner Logo
Partner Logo
Partner Logo

Get in Touch

Interested in learning more about GratXray or our senoa breast CT technology? We're here to answer your questions and discuss how we can support your needs.